Siemens Healthineers and Biogen Announce Agreement to Jointly Develop New MRI Tools for Multiple Sclerosis
January 17 2017 - 10:30AM
Business Wire
- Project will explore quantitative
MRI metrics for more informed treatment decision making
Siemens Healthineers and Biogen have announced that the
companies plan to jointly develop magnetic resonance imaging (MRI)
applications with the intent of quantifying key markers of multiple
sclerosis (MS) disease activity and progression. Biogen is a
leading biotechnology company with a deep focus on neurological and
autoimmune conditions, which for two decades has been at the
forefront of delivering therapies to MS patients. Siemens
Healthineers aims to enable healthcare providers to meet their
current challenges and excel in their respective environments. To
execute this strategy in the field of neurology, Siemens
Healthineers will cooperate with Biogen and contributes its
strength in medical imaging.
“By bringing together the shared expertise of both Siemens
Healthineers and Biogen in imaging and neurology, respectively, we
seek to develop new measurement tools that meet the particular
technical challenges of MS,” said Dr. Christoph Zindel, Senior Vice
President of Magnetic Resonance Imaging at Siemens Healthineers.
“Our shared goal is to create a solution that can be integrated
into the existing radiology workflow, so it can become a seamless
part of routine care – delivering new and valuable information to
treating neurologists without increasing the cost or burden on the
healthcare system.”
MRI is routinely used to support physicians in diagnosing MS,
measuring disease activity and monitoring response to therapy.
Clinicians qualitatively evaluate MRIs by comparing the current MRI
to the previous MRI. Numerous studies have demonstrated that
quantitative MRI measures may provide additional information about
disease prognosis and therapeutic effect, but today quantitative
measurement techniques with the precision and sensitivity required
for MS are typically only available in the research setting. With
the development and validation of automated MRI applications to
quantify key markers of MS, including new T2 lesions and brain
atrophy, patients could benefit from the availability of enhanced
data at the point of care.
“Biogen believes that the availability of high-quality,
standardized data at the point of care can lead to a deeper
understanding of MS, more informed treatment decisions and,
ultimately, improved patient outcomes,” said Richard Rudick, MD,
Vice President Development Sciences, Biogen. “We also recognize
that the ability to generate research-quality data in the course of
routine clinical practice can unlock the potential of the health
care system to move towards precision medicine.”
The products/features (here mentioned) are not commercially
available in all countries. Due to regulatory reasons their future
availability cannot be guaranteed. Further details are available
from the local Siemens organizations.
Siemens Healthineers is the separately managed healthcare
business of Siemens AG enabling healthcare providers worldwide to
meet their current challenges and to excel in their respective
environments. A leader in medical technology, Siemens Healthineers
is constantly innovating its portfolio of products and services in
its core areas of diagnostic and therapeutic imaging and in
laboratory diagnostics and molecular medicine. Siemens Healthineers
is also actively developing its digital health services and
enterprise services. To help customers succeed in today’s dynamic
healthcare marketplace, Siemens Healthineers is championing new
business models that maximize opportunity and minimize risk for
healthcare providers. In fiscal 2016, which ended on September 30,
2016, Siemens Healthineers generated revenue of €13.5 billion and
net income of over €2.3 billion and has about 46,000 employees
worldwide. Further information is available at
www.siemens.com/healthineers.
Through cutting-edge science and medicine, Biogen
discovers, develops and delivers worldwide innovative therapies for
people living with serious neurological, autoimmune and rare
diseases. Founded in 1978, Biogen is one of the world’s oldest
independent biotechnology companies and patients worldwide benefit
from its leading multiple sclerosis and innovative hemophilia
therapies. For more information, please visit www.biogen.com.
Follow us on Twitter.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170117006008/en/
For journalistsSiemens HealthineersUlrich Kuenzel, +49
9131 84-3473Ulrich.Kuenzel@siemens-healthineers.comorBiogenLindsey
Smith, +1 781-464-3260lindsey.smith@biogen.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024